Page **1** of **30**

1 The role of plasmapheresis in snake envenoming: a systematic review

- Hari Prasad¹, Nidhi Kaeley ^{2*}, Jewel Rani Jose³, Ajun U N⁴, Takshak Shankar⁵, Ajmal Salam⁶, Krishna
 Shukla⁷
- 4 1. Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, New 5 Delhi, India, hariprasad007007007@gmail.com 6 2. Head of Department, Department of Emergency Medicine, All India Institute of Medical Sciences, 7 Rishikesh, India, nidhi.em@aiimsrishikesh.edu.in 8 Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, 3. 9 India, jewka4229@gmail.com 10 Senior Research Officer, Department of Psychiatry, National Institute of Mental Health and Neuro 4. 11 Sciences, Bengaluru, India, ajun563@gmail.com 12 5. Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh, 13 India, takshak.shankar@gmx.com Senior Resident, Department of Paediatrics, Aster DM Wayanad Institute of Medical Sciences, Wayanad, 14 6. 15 India, ajmalwims@gmail.com 16 7. DrNB Trainee, Department of Critical Care Medicine, Medanta, The Medicity, Gurgaon, India, 17 krishna.shukla03@gmail.com 18 Correspondence: nidhi.em@aiimsrishikesh.edu.in 19 20 21 22 23 24 25 26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Page **2** of **30**

27 Abstract

Background- Envenoming from numerous sources, such as snakes, scorpions, and spiders, is a major health issue
across the world, resulting in millions of cases and tens of thousands of deaths annually. Venom induced
symptoms ranges from systemic reactions like nausea and vomiting to localised pain and swelling. One major risk
is the development of venom induced consumption coagulopathy (VICC), which might result in significant
consequences. Plasmapheresis is being investigated as a possible therapy for severe envenoming.

Objectives-We aim to assess the effectiveness and potential advantages of plasmapheresis in snakebite cases, focusing on clinical results. We seek to find if plasmapheresis improves neurological, renal, and hematological dysfunction and impacts secondary outcomes, including patient discharge rates, morbidity, mortality, duration of hospital stay, and the number of plasmapheresis sessions required.

37 Methods- Following PRISMA guidelines, we conducted a systematic search of articles published between 1980 38 and July 2023 across multiple databases. MeSH terms related to snakebite and plasmapheresis were applied 39 without publication or language type restrictions. Inclusion criteria considered case reports, cross-sectional 40 studies, or case series featuring plasmapheresis in snakebite management. Inclusions were participants aged 18 41 years or older with confirmed or suspected snakebites, meeting plasmapheresis indications. Exclusions included 42 participants under 18 years, studies reporting only in vitro data, review articles, and redundant reporting. The 43 emphasis was on Emergency Departments or Intensive Care Units.

Results- In a review of 147 cases (1980 to July 2023), the most common snake was the hump-nosed viper
(*Hypnale hypnale*). Renal, neurological, and hematological dysfunctions improved after plasmapheresis. The
mean plasmapheresis sessions were 2.1, and the average hospital stay was 13.13 days.

47 Conclusion- Once the data has been analyzed, the result emphasizes the clinical importance of plasmapheresis in
48 snakebite envenoming. It helps decision-making when standard therapies are insufficient or ineffective,
49 potentially saving lives.

50 Keywords- plasmapheresis, snakebite, snake bite, snakebite envenoming, therapeutic plasma exchange

51

Page **3** of **30**

52 Author Summary

- 53 Snakebites pose a significant global health threat, causing numerous deaths and serious injuries annually. While
 54 antivenom is the primary treatment, it's not always effective or available. This study explores an alternative
 55 treatment called plasmapheresis, a method that filters harmful substances from the blood.
- 56 We reviewed 147 cases of snake envenoming treated with plasmapheresis between 1980 and 2023. Our findings
- 57 show that plasmapheresis can improve various complications caused by snake venom, including kidney problems,
- nerve damage, and blood disorders. On average, patients received about two plasmapheresis treatments and stayed
- in the hospital for around 13 days.

60 The study suggests that plasmapheresis could be a valuable option when standard treatments aren't working well 61 enough. It might help save lives in severe cases of snake envenoming. While more research is needed, this review 62 provides important insights for doctors treating snakebite victims, especially in areas where snakebites are 63 common and resources are limited.

64 Background

Envenoming causes significant morbidity and mortality; the most common causes are snakes, scorpions, spiders,
bugs, and unidentified bites [1]. According to the World Health Organisation (WHO), there are 2.7 million snake
bites globally each year, resulting in 81,000 to 138,000 deaths [2]. Snakebite is classified as a category A
Neglected Tropical Disease (NTD) by the WHO [3]. Each year, there are over 81,000 occurrences of snakebite
envenoming in India, resulting in 11,000 fatalities [4].

Indian Cobra (Naja Naja), Russell's Viper (*Daboia russelii*), and Krait (*Bungarus caeruleus*) are among the most harmful and venomous snakes. Examples of local symptoms include painful regional lymphadenopathy, edema, and discomfort at the bite site. Nausea, vomiting, headaches, diaphoresis, stomach discomfort, and diarrhoea are examples of non-specific systemic symptoms. Toxin syndromes such as neurotoxicity, myotoxicity, and VICC can result from systemic envenoming [5]. Some elapid envenomings cause hemostatic and cardiovascular consequences [6].

Acute kidney injury (AKI), VICC, and tissue destruction are all caused by metalloproteinases, phospholipase A2,
and snake lectins, in hematotoxic venom. The major toxin-mediated coagulopathy brought on by a hemotoxic
snakebite is VICC, which is then followed by venom-induced Thrombotic Microangiopathy (TMA) and Diffuse

Page 4 of 30

79 Alveolar Hemorrhage (DAH) [7,8]. Russell's viper (Daboia russelii) envenoming causes a specific condition 80 known as Capillary Leak Syndrome (CLS) [9]. Drowsiness, visual abnormalities, and respiratory failure are 81 neurotoxicity signs [6]. Rarely, a snakebite can result in Guillain-Barre Syndrome (GBS) and Insulin Autoimmune 82 Syndrome (IAS), which is treatable with plasmapheresis. For AKI, hemotoxic consequences, CLS, hemodialysis, 83 and antisnake venom are used. But for many, plasmapheresis is a last-ditch option. Plasma exchange is an alternate 84 method for removing venom toxins that are difficult to remove using dialysis or hemoperfusion. Venom toxins 85 can be effectively removed from the blood by plasma exchange but not from other fluid compartments. Plasma 86 exchange may help to reduce venom toxins in the blood compartment and may even cause venom toxins to be 87 redistributed and removed from the extravascular region. Kornalik reported the first instance of plasma exchange 88 being utilized to treat snake bite envenoming in 1990. Rasulov and Berdymuradov reported using plasma 89 exchange in 1994 to treat three of 24 patients who had been bitten by snakes and become envenomed. Zengin et 90 al. found plasmapheresis to be an effective intervention in a retrospective study of 37 snakebite patients with 91 complications not resolving with antivenom administration [10]. Herein, we aim to conduct a systematic review 92 to assess the effectiveness of plasmapheresis in snakebite cases and the situations under which it may be beneficial.

93 Methods

94 Search strategy


95 PROSPERO (ID: CRD42023459261) was used to register the study protocol. Prior to the start of the systematic 96 review, a protocol was created using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-97 Analyses). A comprehensive search approach for articles from 1980 to July 2023 was carried out. PubMed, 98 Embase via Elsevier, MEDLINE via Ovid, The Cochrane Library for Cochrane Reviews, Scopus, Web of Science, 99 and Google Scholar were searched with the MeSH terms 'bite' or 'snakebite' or 'envenomation' or 'snakebite 100 envenoming' and 'plasmapheresis' or 'therapeutic plasma exchange.' Additionally, we contacted the research 101 authors for any missing data, manually checked the reference lists of the included studies, and utilised a database's 102 similar articles function.

103 Study selection and screening

104 HP, NK, and JJ independently screened search results for eligibility. For articles eligible after screening, full texts 105 were retrieved by HP, NK, and JJ, which HP, JJ, NK, AU, TS, AS and KS reviewed. HP and JJ screen the citation 106 search. Discrepancies were resolved by consensus. The selection process was done as in Fig. 1 [11].

medRxiv preprint doi: https://doi.org/10.1101/2024.09.27.24314476; this version posted September 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity

perpetuity. It is made available under a CC-BY 4.0 International license .



107

108 Fig. 1- PRISMA above shows the flow of patients.

109 Eligibility Criteria

This review aimed to find, assess, and synthesize all cross-sectional studies, case reports, or case series that used plasmapheresis for snakebite along with conventional Anti Snake Venom (ASV), atropine-neostigmine, calcium gluconate or hemodialysis. Only human cases aged more than 18 years, suspected or confirmed snakebites or those who fulfill indications of plasmapheresis were included in the review. We excluded Human cases under 18 years, studies reporting in vitro data only, review articles, or those with complete reporting overlap. The study was set in an Emergency Department or Intensive Care Unit as patients with complications mostly come here.

116

Page **6** of **30**

117 Data extraction

- 118 HP and JJ were the authors who extracted the data. Each included study provided the following data regarding
- 119 study characteristics and outcomes:
- Study types: observational studies
- The study's methods included: Authors of the study, year, and study design
- The intervention(s) of interest: kind, frequency, and comparator(s) used: normal care
- Age, gender, and the outcomes listed above were characteristics of the participants' studies.

124 Assessment of the Risk of Bias

- 125 The risk of bias for each research was independently assessed by five review authors (NK, AN, TS, HP, JJ, AS
- and KS) using the Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case
- series and case reports. BMJ Evid-Based Med. 2018;23(2): 60–3 [12].

128 Outcome

The study's primary outcomes were 'improvement in renal dysfunction' defined as patients becoming KDIGO 1 at discharge, 'improvement in neurological dysfunction' defined as Guillain Barre Syndrome disability score 0-2 at discharge, or 'improvement in hematological dysfunction' described as hemoglobin and platelets returning to age-appropriate normal limits without schistocytes following plasmapheresis done for snakebite. The secondary outcomes were discharge or death, morbidity (KDIGO 2 or3, Guillain Barre Syndrome disability score 3-5, no return to age-appropriate limits for hemoglobin and platelets), hospital stay duration, and number of plasmapheresis. This helps to determine the role of plasmapheresis and its effectiveness in the snakebite.

136 Analysis

137 The mean and standard deviation for normal distributions, the median (interquartile range) for non-normal 138 distributions of numerical variables, and percentages and proportions for categorical variables were the ways in 139 which descriptive statistics were stated. The data was analysed using SPSS 23.0.

Page **7** of **30**

140 Results

- This systematic review includes 147 patients from 40 studies carried out between 1980 and July 2023. The 141 142 population's average age was 49.9 ± 14 years, with 59.9% of patients being male.
- 143 Main results: Regarding the types of snake bites, 77 cases involved unidentified snake species, while the hump-144 nosed viper (Hypnale hypnale, one of which is Hypnale zara) accounted for most known snakebites (42). This 145 was followed by eight each for Russell's viper (Daboia russelii) and saw-scaled viper (five Echis carinatus, one 146 Echis pyramidum, one Echis coloratus, one Echis sochureki), three pit vipers (two Bothrops asper, one Crotalus 147 cerastes), and other viper species (Proatheris superciliaris, Cerastes cerastes) accounting for two. Additionally, 148 there were three krait bites (one Bungarus caeruleus, one Bungarus multicinctus, one Bungarus candidus), one 149 sea snake bite (Hydrophis platurus), one Australian brown snake bite (Pseudonaja nuchalis), one taipan bite 150 (Oxyuranus scutellatus), and one Colubridae snake bite (Notechis scutatus).
- A summary table showing study included, type of snake, indication for plasmapheresis and geographical location 151 152
- of snakebite are shown in Tabe 1.

Sl.No	Author	Study	Snake	Indication	Geographical
					Location
1.	Yildirim et al. [13]	Retrospective	N/A	VICC	Turkey
		descriptive			
		study			
2.	Arora et al. [14]	Case report	Daboia russelii	ТМА	India
3.	Mohan et al. [15]	Case report	Daboia russelii	ТМА	India
4.	Zengin et al. [10]	Retrospective	N/A	VICC	Turkey
		observational			
		study			
5.	Berber et al. [16]	Observational	N/A	VICC	Turkey
		study			

153 Table 1: Summary Table

6.	Dineshkumar et	Case report	Daboia russelii	ТМА	India
	al. [17]				
7.	Erkurt et al. [18]	Retrospective observational study	N/A	VICC	Turkey
8.	Rathnayaka et al. [19]	Prospective observational study	Hypnale hypnale	ТМА	Srilanka
9.	Isbister et al. [20]	prospective observational study	Pseudonaja nuchalis	ТМА	Australia
10.	Rahmani et al. [21]	Case series	Echis coloratus	ТМА	Israel
11.	Obeidat et al. [22]	Case Report	Echis carinatus	ТМА	Jordan
12.	Keyler et al. [23]	Case Report	Proatheris superciliaris	ТМА	USA
13.	Kornalík et al. [24]	Case Report	Bothrops asper	VICC	Czechoslovakia.
14.	Valenta et al. [25]	Case Report	Echis pyramidum	ТМА	Czech Republic
15.	Sampley et al. [26]	Case Report	N/A	DAH	India
16.	Grace et al. [27]	Case Report	N/A	CLS	India
17.	Hameed et al. [28]	Case Report	Hydrophis platurus	GBS	Pakistan
18.	Cobcroft et al. [29]	Case Report	Oxyuranus scutellatus	ТМА	Australia
19.	Chuang et al. [30]	Case Report	Bungarus multicinctus	GBS	Taiwan

20.	Akhilesh Kumar	Case Report	Echis sochureki	DAH	India
	et al. [8]				
21.	Withana et al. [31]	Case Report	Hypnale	ТМА	Srilanka
			hypnale		
22.	Mitrakrishnan et	Case Report	Hypnale	ТМА	Srilanka
	al. [32]		hypnale		
23.	Rathnayaka et al.	Case Series	Daboia russelii	ТМА	Srilanka
	[33]				
24.	Srivastava et al.	Case Report	N/A	GBS	India
	[34]				
25.	Reddy et al. [35]	Case Report	Daboia russelii	ТМА	India
26.	Cañas et al. [36]	Case Report	Bothrops asper	ТМА	Colombia
27.	Rathnayaka et al.	Case report	Hypnale zara	ТМА	Srilanka
	[37]				
28.	Godavari et al.	Case Report	N/A	ТМА	India
	[38]				
29.	Murthy et al. [39]	Case Report	N/A	ТМА	India
30.	Wijewickrama et	Prospective	Hypnale	ТМА	Srilanka
	al. [40]	observational	hypnale		
		study			
31.	Janarthanam et al.	Case Report	Crotalus	GBS	India
	[41]		cerastes		
32.	Senthilkumaran et	Case Report	Bungarus	IAS	India
	al. [42]		caeruleus		
33.	Priyankara et al.	Case Report	Daboia russelii	ТМА	Srilanka
	[43]				
34.	Laothong et al.	Case Series	Bungarus	GBS	Thailand
	[44]		candidus		

35.	Herath et al. [45]	case series	Hypnale	ТМА	Srilanka
			hypnale		
36.	Bava et al. [46]	Case series	Echis carinatus	DAH, VICC,	India
				ТМА	
37.	Elmoqaddem et	Case report	Cerastes	VICC	Morocco
	al. [47]		cerastes		
38.	Casamento et al.	Case Series	Notechis	ТМА	Australia
	[48]		scutatus		

154 CLS, Capillary Leak Syndrome; DAH, Diffuse Alveolar Hemorrhage; GBS, Guillain-Barre Syndrome; IAS, 155 Insulin Autoimmune Syndrome; TMA, Thrombotic Microangiopathy; USA, United States of America; VICC, 156 venom-induced consumption coagulopathy

157 Among the indications for plasmapheresis, the majority (51%) was performed for VICC, while 42.2% of cases were for TMA and 3.4% for GBS. Three cases involved DAH, and one each involved CLS and IAS, all of which 158 159 underwent plasmapheresis.

Sl.No	Author	Number	Age or	Sex (Number	Renal	Neurological	Blood
		of	Range	of	dysfunction	dysfunction	dysfunction
		patients		Male/Female)	present or	present or	present or
		*			not. If yes	not. If yes	not. If yes
					improved or	improved or	improved or
					deteriorated	deteriorated	deteriorated
					following	following	following
					TPE	TPE	TPE
1.	Yildirim et al.	13	21-75	9/4	-	-	Yes,
	[13]						Improved
2.	Arora et al. [14]	1	44	1/-	Yes,	-	Yes,
					Improved		Improved
3.	Mohan et al.	1	70	-/1	Yes,	-	Yes,
	[15]				Improved		Improved

Page **11** of **30**

4.	Zengin et al.	33	20-79	19/14	Yes,	-	Yes,
	[10]				Improved		Improved
5.	Berber et al.	20	49.55	17/3	Yes, 19	-	Yes, 19
	[16]				improved 1		improved 1
					Death		Death
6.	Dineshkumar et	1	56	1/-	Yes/ Not	-	Yes/
	al. [17]				improved-		Improved
					ESRD		
7.	Erkurt et al. [18]	5	21-80	1/4	Yes,		Yes,
					Improved		Improved
8.	Rathnayaka et	21	29-70	14/7	Yes/ 16	-	Yes/ 20
	al. [19]				improved 5		improved 1
					Not		Not
					improved (1		improved-
					Death, 4		Death
					ESRD)		
9.	Isbister et al.	1	42	1/-	Yes,	-	Yes,
	[20]				Improved		Improved
10.	Rahmani et al.	2	39,70	2/-	Yes,	-	Yes,
	[21]				Improved		Improved
11.	Obeidat et al.	1	25	1/-	Yes,	-	Yes,
	[22]				Improved		Improved
12.	Keyler et al.	1	27	1/-	Yes,	-	Yes,
	[23]				Improved		Improved
13.	Kornalík et al.	1	60	1/-	-	-	Yes,
	[24]						Improved
14.	Valenta et al.	1	41	1/-	Yes,	-	Yes,
	[25]				Improved		Improved
15.	Sampley et al.	1	36	1/-	Yes,	-	Yes,
	[26]€				Improved		Improved

Page **12** of **30**

16.	Grace et al. [27]	1	28	1/-	Yes,	-	Yes,
	3				Improved		Improved
17.	Hameed et al.	1	21	1/-	-	Yes/ Not	-
	[28]					improved-	
						Neurodeficit	
18.	Cobcroft et al.	1	33	1/-	Yes/ Not	-	Yes/ Not
	[29]				improved-		improved-
					Death		Death
19.	Chuang et al.	1	36	1/-	-	Yes/	-
	[30]					Improved	
20.	Akhilesh	1	40	1/-	-	-	Yes,
	Kumar et al. [8]						Improved
	Ω						
21.	Withana et al.	1	55	-/1	Yes,	-	Yes,
	[31]				Improved		Improved
22.	Mitrakrishnan	1	70	1/-	Yes,	-	Yes,
	et al. [32]				Improved		Improved
23.	Rathnayaka et	1	66	-/1	Yes, Not	-	Yes,
	al. [33]				Improved-		Improved
					ESRD		
24.	Srivastava et al.	1	40	1/-	-	Yes,	-
	[34]					Improved	
25.	Reddy et al.	1	55	-/1	Yes,	-	Yes,
	[35]				Improved		Improved
26.	Cañas et al. [36]	1	57	1/-	Yes,	-	Yes,
					Improved		Improved
27.	Rathnayaka et	3	55-74	2/1	Yes,	-	Yes,
	al. [37]				Improved		Improved
28.	Godavari et al.	2	30,49	1/1	Yes,	-	Yes,
	[38]				Improved		Improved

29.	Murthy et al.	1	51	1/-	Yes,	-	Yes,
	[39]				Improved		Improved
30.	Wijewickrama	9	39-59	3/6	Yes,	-	Yes,
	et al. [40]				Improved		Improved
31.	Janarthanam et	1	29	-/1	-	Yes,	-
	al. [41]					Improved	
32.	Senthilkumaran	1	54	-/1	-	-	-
	et al. [42] #						
33.	Priyankara et al.	1	70	-/1	Yes,	-	Yes,
	[43]				Improved		Improved
34.	Laothong et al.	1	35	1/-	-	Yes,	-
	[44]					Improved \$	
35.	Herath et al.	7	44-76	3/4	Yes/ 3	-	Yes, 5
	[45]				Improved 4		Improved, 2
					Not		Not
					improved (2		improved-
					Death, 2		Death
					ESRD)		
36.	Bava et al. [46]	3	40-50	2/1	Yes, 2	-	Yes, 2
	¥				Improved		Improved
37.	Elmoqaddem et	1	43	1/-	Yes,	-	-
	al. [47]				Improved		
38.	Casamento et al.	1	55	-/1	Yes,	-	Yes,
	[48]				Improved		Improved

160 ESRD End Stage Renal Disease

161 * Number of patients with snakebite as per inclusion criteria of the review

162 #- Patient with Insulin Autoimmune syndrome post snakebite improved following TPE

Page **14** of **30**

163	€ This patient with DAH post snakebite had concomitant renal and blood dysfunction too all 3 improved following
164	ТРЕ

3 This patient with CLS post snakebite had concomitant renal and blood dysfunction too all 3 improved followingTPE

167 Ω This patient with DAH post snakebite had concomitant blood dysfunction both of which improved following
 168 TPE

- 169 \$ Improved but have persistent autonomic dysfunction

170 ¥ Patient with DAH post snakebite improved following TPE

171

Of the 124 patients who developed renal dysfunction, 112 showed improvement after plasmapheresis. Five of the eight patients who developed neurological dysfunction showed improvement after plasmapheresis. Of the 136 patients who developed hematological derangements, 124 improved after plasmapheresis. Furthermore, one patient with IAS who developed autonomic dysfunction also improved after plasmapheresis.


From the available data, 90.5% of patients were discharged from the hospital, while nine patients succumbed to
death. Among the patients, 86.4% did not develop residual clinical effects on discharge (no morbidity), 7.5%
developed end-stage renal disease, two developed residual limb weakness, and one developed autoimmune
dysfunction. Relation of indication for plasmapheresis and duration of hospital stay is shown in Fig. 2.

180

181 Fig. 2: Mean duration of hospital stay and indications of plasmapheresis

182

Page 15 of 30



184 Fig. 2: Bar diagram showing mean duration of hospital stay with plasmapheresis indications

185 CLS, Capillary Leak Syndrome; DAH, Diffuse Alveolar Hemorrhage; GBS, Guillain-Barre Syndrome; IAS, Insulin Autoimmune Syndrome; TMA, Thrombotic Microangiopathy; VICC, venom-induced 186 187 consumption coagulopathy

188 The duration of hospital stay showed high variability, ranging from 1 to 65 days, with a mean of 13.1 days. The 189 number of plasmapheresis sessions ranged from 1 to 14, with a median of 2 and an interquartile range (IQR) of 190 (1,4). Day

191 Discussion

183

192 Snakebites are an occupational danger, with the majority of bites occurring on farms when working barefoot or 193 wandering through the fields at night. The four families of venomous snakes are the Elapidae, Viperidae, 194 Hydrophidae, and Colubridae. Elapid venom's most prevalent clinical effects are neurotoxic, whereas viper venom 195 causes vascular toxicity and nephropathy, and Hydrophiinae or sea snake venom is myotoxic [49].

196 AKI is a common complication of snakebite and a significant cause of death and morbidity. 75% of instances of 197 AKI in this situation are caused by acute tubular necrosis (ATN), while 5-15% of cases are caused by acute 198 interstitial nephritis (AIN) [38]. The prevalence of AKI following Russell's viper (Daboia russelii) and Echis 199 carinatus bites ranges from 13 to 32%. Pathogenesis of AKI in snake envenoming involves hemolysis, 200 rhabdomyolysis, DIC, sepsis, hemodynamic abnormalities, and cell damage caused by the production of 201 proinflammatory cytokines and vasoactive mediators [17,38].

202 Venom induced consumption coagulopathy (VICC)

Page **16** of **30**

203 The hemotoxic venom activates coagulation pathways leading to VICC without thrombocytopenia and is 204 characterized by severe bleeding without visible fibrin deposition, microvascular thrombosis, or end-organ failure, 205 which results from snake toxins activating the coagulation pathway. This results in a prolonged prothrombin time, 206 increased fibrinogen consumption, and elevated D-dimer levels, all overlapping with DIC. TMA appears in a 207 subset of individuals with or without VICC whom a snake bite has envenoming. While the coagulopathy in VICC 208 resolves rapidly, the triad of TMA (AKI, thrombocytopenia, and microangiopathic hemolytic anemia) persists for 209 longer. Most cases of TMA following snake envenoming have been documented in Sri Lanka and Australia; very 210 few cases have been reported in India. The proposed mechanism is that venom or its vascular endothelial toxins 211 may function as factors related to VEGF or von Willebrand factor (vWF) activators and cause endothelium 212 damage to initiate TMA. The role of ADAMTS-13, a VWF-cleaving protease, in snake bites requires more 213 investigation [14,17].

214 The symptoms of TMA often begin 1-3 days after the bite and last longer than those of VICC, which typically 215 resolves after 12-24 h of antivenom infusion. According to Bull et al., either the presence of intravascular fibrin 216 or endothelial injury may predispose to fibrin deposition [50]. These data show that TMA may not always be the 217 same as VICC. Certain species, including B. jararaca, induce TMA by up-regulating and activating the genes that 218 produce inflammatory mediators such matrix metalloproteinase (MMP)-10, IL-8, VCAM-1, and E-selectin. 219 Jararhagin, a hemorrhagic metalloproteinase discovered from B. jararaca venom, may cause a systemic 220 proinflammatory response [51,52].

221 The ecarin enzyme converts prothrombin directly into meizothrombin and is primarily responsible for the 222 pathophysiology of envenoming in members of the Echis genus. Disintegrins, including echistatin, ocellatin, and 223 pyramidin, are other venom components that prevent platelet aggregation [53]. Hemorrhaging-like substances 224 exacerbate prothrombotic activation and the production of fibrin deposits and lead to afibrinogenemia [25].

225 TPE for VICC was done in 51.1% of the study's subjects, with 98.6% having their blood dysfunction improved. 226 227 **Thrombotic Micro Angiopathy (TMA)**

228 TMA is a pathological diagnosis and is associated with acute kidney injury (AKI), Microangiopathic Hemolytic 229 Anemia (MAHA) and thrombocytopenia. Thrombotic thrombocytopaenic purpura (TTP) and haemolytic uraemic 230 syndrome (HUS) are the prototype diseases associated with TMA. The first is thrombotic thrombocytopenic 231 purpura (TTP), which was discovered in 1925 in a 16-year-old female patient by Eli Moschcowitz. The second 232 condition is hemolytic uremic syndrome (HUS), which was discovered by Gasser in 1955 in five newborns who

Page **17** of **30**

had renal failure, thrombocytopenia, and hemolytic anaemia as a result of a diarrheal sickness [54,55]. Bite-related
HUS or HUS-like alterations in Western Australia have been linked to gwadar (*Demansia nuchalis nuchalis*),
dugite (*Demansia nuchalis affinis*), and Russell's viper (*Daboia russelii*) bites in India. The difference between
HUS and TTP is a little arbitrary because there is much overlap between the two, and it would be preferable to
think of them as a continuum of a related disease process [29].

TMA is not included in the categories of complement factor dysregulation or ADAMTS 13 deficiency. The primary cause of TMA pathogenesis, according to the study, is endothelial cell damage or dysfunction, which exposes thrombogenic components to coagulation factors and platelets. Endothelial damage occurs as a result of uncontrolled inflammation and/or genetic or acquired abnormalities of complement or hemostasis mediators, as shown in TMA. TPE may be considered as a therapy option for such people if TMA is shown to be the consequence of snake envenoming [15]. TPE for TMA was done in 42.2 % of the study's subjects, with 77.76 % having their renal dysfunction improved and 92.5% have their blood dysfunction improved.

245 Guillain Barre Syndrome (GBS)

246 The first instance of GBS associated with a snakebite was reported by Chuang et al. in 1996. Four weeks after

247 being bitten by a Bungarus multicinctus, sensorimotor axonal-type polyneuropathy was identified by

248 EMG/NCS. After therapy (plasmapheresis and 500 mg/day of methylprednisolone for five days), the patient's

condition improved [30]. In 2010, Srivastava et al. reported that EMG/NCS revealed motor and sensory

250 neuropathy five weeks after the bite, indicating demyelination with subsequent axonal degradation.

251 Plasmapheresis aided the patient's recovery [34]. Neil et al. (2011) described a patient who experienced

252 paraesthesia and quadriparesis 12 days after being bitten by a Vipera aspis snake. The researchers discovered

253 molecular similarity between venom proteins and neuronal GM2 gangliosides, hypothesising an immunological

explanation rather than direct venom toxicity for this relationship [28,56]. TPE for GBS was performed on

255 3.4% of the study's individuals, with four of them having neurological dysfunction improved and one having

256 neurodeficit. One of those who improved had persisting autonomic dysfunction.

257 Diffuse Alveolar Hemorrhage (DAH)

258 DAH is a potentially fatal pulmonary complication in various conditions characterized by hypoxemia caused by

alveolar infiltrates, which leads to alveolar hemorrhage and necessitates rapid treatment and lifesaving

260 measures. DAH's causes can be immunological and non-immune. The pathophysiology includes widespread

alveolar destruction, alveolar hemorrhage, and antibody-mediated pulmonary capillaritis. Direct venom action

Page **18** of **30**

262	and/or an insult mediated by an antibody might account for the delayed DAH by causing widespread alveolar
263	injury. Sampley et al. described DAH in viper envenoming during the first week, with a normal coagulation
264	profile controlled with methylprednisolone and plasmapheresis. The effective use of plasmapheresis and
265	methylprednisolone in DAH on day three following a hump-nosed pit viper (Hypnale hypnale) bite, including
266	VICC and thrombotic microangiopathy, was described by Srirangan et al. Therefore, plasma exchange has a
267	limited role in the treatment of snakebite despite evidence supporting its use in thrombotic microangiopathy
268	[8,26]. TPE was performed on three individuals with DAH, two of whom had concurrent blood malfunction and

269 one of whom had concurrent renal impairment. All of which improved after TPE.

270 Capillary Leak Syndrome (CLS)

271 Dr. Bayard Clarkson discovered CLS, also known as Clarkson's illness, in 1960. Its defining features are 272 hemoconcentration, hypotension, generalized edema, and hypoalbuminemia without albuminuria [57]. Capillary 273 hyperpermeability and plasma extravasation are the essential mechanisms. CLS can develop as a primary 274 (idiopathic) disorder or a complication of other illnesses. Snake venom contains toxins and enzymes that promote 275 capillary permeability and cause plasma to escape from the intravascular region. The clinical appearance of CLS 276 goes through three stages. First, a prodromal phase of irritation, myalgia, thirst, and syncope. Second, the capillary 277 leakage phase is characterized by intravascular fluid extravasation. Third, complication phase-renal failure is a 278 frequent complication [27]. There are no recognized diagnostic criteria, but with minor revisions, the Thomas and 279 Kumar criteria can be used for diagnosis.

Treatment includes theophylline, leukotriene antagonists, terbutaline, plasmapheresis, corticosteroids, and intravenous immunoglobulin (IG), disease-modifying therapy medications. The outlook for CLS is still quite bad because there is no established treatment. We hypothesized that the patient's favorable result may have been influenced by early CLS detection, timely plasmapheresis implementation, and the use of fresh frozen plasma [58]. TPE was done for one patient with CLS post snakebite who had concomitant renal and blood dysfunction too all of which improved following treatment.

286 Insulin Autoimmune Syndrome (IAS)

In the early 1970s, Hirata and colleagues described Insulin Autoimmune Syndrome (IAS). Postprandial hypoglycemia, increased insulin levels, and detectable insulin antibodies are all indications of IAS. These antibodies, most often IgG, are considered to bind to circulating insulin and inhibit its interaction with its receptor.

Page **19** of **30**

290 There have been a few accounts of a snakebite-inducing IAS. Many biomolecules in snake venom have the 291 potential to be antigenic. Common krait's (Bungarus caeruleus) venom may contain a compound with structural 292 resemblance to endogenous insulin, leading to the production of antibodies against its epitope, or venoms could 293 include substances that reduce disulfide and cause the production of monomers. The existence of the HLA-294 DRB1*0406 allele has been linked to the onset of IAS. Dextrose infusions, corticosteroids, somatostatin, 295 diazoxide, azathioprine, rituximab, metformin, dietary changes, and plasmapheresis have all been used to treat 296 IAS. Plasmapheresis rapidly decreased the patient's autoantibody level and reversed their condition. Therefore, 297 once the diagnosis has been made, particularly for individuals with krait (Bungarus caeruleus) envenoming, early 298 usage of plasmapheresis will be beneficial [42]. One patient with Insulin Autoimmune syndrome post snakebite 299 was there in study who improved following TPE

300

301 Plasmapheresis

302 Plasma exchange is an alternate method for removing venom toxins that are difficult to remove using dialysis or 303 hemoperfusion. Venom toxins can be effectively removed from the blood by plasma exchange but not from other 304 fluid compartments. Plasma exchange may help to reduce venom toxins in the blood compartment and may even 305 cause venom toxins to be redistributed and removed from the extravascular region. Kornalik reported the first 306 instance of plasma exchange being utilized to treat snake bite envenoming in 1990. Rasulov and Berdymuradov 307 reported using plasma exchange in 1994 to treat three of 24 patients who had been bitten by snakes and become 308 envenomed. Zengin et al. found plasmapheresis to be an effective intervention in a retrospective study of 37 309 snakebite patients with complications not resolving with antivenom administration [10].

310 Plasmapheresis has been utilized to treat TMA caused by snake bites in the absence of antivenom. Plasma 311 exchange therapy should be started before a laboratory test can definitively establish the diagnosis because of the 312 substantial mortality risk associated with TTP. This lack of supporting evidence shows that plasma exchange has 313 only a minor role in snakebite envenoming. Therapeutic plasma exchange for snakebite envenoming is classified 314 as Category III, grade 2 C by the American Society for Apheresis (ASFA) (poor recommendation, low-quality or 315 extremely low-quality evidence) [8].

316 According to the ASFA criteria, acquired TTP is a category I indication for TPE (grade 1A evidence). TPE has 317 two advantages: it eliminates autoantibodies against ADAMTS13 and infuses donor plasma with exogenous

Page **20** of **30**

ADAMTS13 enzyme. The ASFA classified (Shiga like Toxin-Producing E.coli) STEC-HUS as category IV. The argument for using TPE in aHUS is that when allogeneic donor plasma is utilized as the replacement fluid for the exchange; this treatment will eliminate the faulty complement proteins and autoantibodies against complement factor H (CFH). According to ASFA recommendations, TPE is a second-line treatment for patients with additional complement mutations (category II, grade 2C) and a first-line treatment for those who have anti-CFH autoantibodies (category I, grade 2C) [23,59].

324 Other indications for plasmapheresis include Guillain-Barré syndrome, ANCA-associated and Goodpasture 325 glomerulonephritis, chronic demyelinating polyradiculoneuropathy, recurrent focal segmental 326 glomerulosclerosis, hyperviscosity in monoclonal gammopathies, myasthenia gravis, and encephalitis (Category 327 1). Acute encephalomyelitis, cardiac and stem cell transplantation desensitisation, antiphospholipid syndrome, 328 cryoglobulinemia, cardiomyopathy, Hashimoto encephalopathy, Lambert-Eaton syndrome, multiple sclerosis, 329 and myeloma nephropathy (Category 2) are also included. Category 3 indications include acute liver failure, 330 autoimmune hemolytic anaemia, burn shock, newborn lupus, chronic encephalitis, heparin-induced 331 thrombocytopenia, pancreatitis, refractory thrombocytopenia, paraneoplastic syndromes, sepsis, and vasculitis. 332 Systemic amyloidosis, dermatomyositis/polymyositis, and lupus nephritis are all classified under Category 4 [60].

333 Contraindications for therapeutic plasmapheresis include lack of central line access or large bore peripheral lines, 334 hemodynamic instability or septicemia, a known allergy to fresh frozen plasma or replacement colloid/albumin, 335 or heparin; relative contraindications include hypocalcemia and angiotensin-converting enzyme (ACE) inhibitor 336 use within the previous 24 hours [61]. Complications of plasmapheresis are hypocalcemia or hypomagnesemia 337 due to citrate anticoagulation, hypotension, flushing, nausea and vomitinghypothermia, fluid and electrolyte 338 imbalances, transfusion reactions, thrombocytopenia and hypofibrinogenemia causing bleeding diatheses [62]. 339 Plasmapheresis is an effective treatment for a variety of acute and chronic conditions. It may also be used to help 340 prepare for operations and surgeries, as well as to support postoperative recovery and minimise respiration 341 periods. In general, the risks and side effects are minor, with the most prevalent being brief hypotension and 342 associated symptoms [63].

However, antivenom should be administered as soon as feasible, and plasma exchange should be considered as a
supplemental therapy strategy for patients with severe envenoming, particularly in managing hematologic issues
and limb preservation/salvage techniques. We believe that plasma exchange treatment is advantageous because it

Page **21** of **30**

- eliminates toxins and inflammatory mediators. If the envenoming from a snake bite cannot be adequately treatedusing standard methods, plasma exchange may be explored as part of the treatment [10].
- 348 So, we propose that plasmapheresis could be used in snakebites in complications such as VICC, TMA, GBS,
- 349 DAH, CLS, and IAS. Given the rarity of presentation and lack of evidence, plasma exchange could be a lifesaving
- intervention in some circumstances. The effectiveness of plasma exchange in treating snake bite envenoming
- 351 should be clarified by conducting extensive randomized controlled trials.

352 Limitations and strengths

We have included only case series, case reports, and cross-sectional studies as it is challenging to carry out a randomized controlled trial, case-control, or cohort study. The risk of bias was assessed by a nonconventional method using Murad et al. Comparative studies of hemodialysis versus plasmapheresis are required. Plasmapheresis is a costly procedure, and widespread availability is a concern.

The study's strength is that it is one of the first to analyze the role of plasmapheresis in snake bite and to list the indications when plasmapheresis may be used in snakebites.

359

360 Conclusion

Snakebites are serious occupational hazards particularly affecting people in agricultural contexts. Various snake 361 venoms have diverse toxicological profiles, including neurotoxicity, vascular toxicity, nephropathy, and 362 363 myotoxicity. Acute kidney damage (AKI) is a common and serious complication of snakebite, usually caused by 364 acute tubular necrosis. Hemotoxic venoms can cause coagulopathies, resulting in thrombotic microangiopathy (TMA), which is characterised by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic 365 366 anaemia. Plasma exchange (plasmapheresis) has emerged as a potential therapeutic option for snakebite 367 complications such as TMA, Guillain-Barré syndrome, diffuse alveolar haemorrhage (DAH), and capillary leak 368 syndrome (CLS). Despite limited evidence, plasmapheresis can be life-saving by removing toxins and 369 inflammatory mediators from the circulation. It is especially useful when conventional therapies are insufficient. 370 Randomised controlled trials are required for establishing the effectiveness of plasmapheresis in snakebite 371 envenoming, however its use as an adjuvant treatment shows promise for improving patient outcomes in severe 372 envenoming.

373 Acknowledgements

Page **22** of **30**

374 None

375 Author Contributions

- 376 NK had full access to all of the study's data and accepts responsibility for the data's integrity and the correctness
- 377 of the data analysis. As co-first authors, HP and JRJ contributed equally.
- 378 Corresponding author: NK
- 379 Concept and design: HP, NK, JRJ, AU, TS, AS, KS.
- 380 Acquisition, analysis, or interpretation of data: HP, JRJ, AU.
- 381 Drafting of the manuscript: HP, NK, JRJ, AS, AU, TS, KS
- 382 Critical revision of the manuscript for important intellectual content: HP, JRJ, NK, AS, KS, AU, TS
- 383 Statistical analysis: AU, HP, JRJ.
- 384 Administrative, technical, or material support: NK.
- 385 Supervision: HP, JRJ, NK, AS, KS, TS, AU
- 386 Funding
- 387 None.

388 Availability of data and materials

- 389 The datasets generated during and/or analysed during the current study are available from the corresponding
- author on reasonable request.
- 391 Declarations
- 392 Ethics approval and consent to participate
- 393 Not applicable.
- **394 Consent for publication**
- 395 Not applicable
- **396** Competing interests

Page **23** of **30**

- 397 The authors declare that they have no competing interests.
- 398 Author Information
- 399 HP, Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 400 India, hariprasad007007007@gmail.com
- 401 NK, Head of Department, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 402 India, <u>nidhi.em@aiimsrishikesh.edu.in</u>
- 403 JRJ, Junior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 404 India, jewka4229@gmail.com
- 405 AU, Junior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences,
- 406 Rishikesh, India, ajun563@gmail.com
- 407 TS, Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences, Rishikesh,
- 408 India, takshak.shankar@gmx.com
- AS, Junior Resident, Department of Paediatrics, All India Institute of Medical Sciences, Rishikesh, India,
 ajmalwims@gmail.com
- 411 KS, MD, Senior Resident, Department of Emergency Medicine, All India Institute of Medical Sciences,
- 412 Rishikesh, India, <u>krishna.shukla03@gmail.com</u>

413 References

414 1. White J. Bites and stings from venomous animals: a global overview. Ther Drug Monit. 2000;22(1):65–8.

415 2. World Health Organization. Snakebite envenoming: a strategy for prevention and control [Internet]. 416 Geneva: World Health Organization; 2019 [cited] 2023 Aug 18]. 50 Available from: p. 417 https://apps.who.int/iris/handle/10665/324838

Lancet T. Snake-bite envenoming: a priority neglected tropical disease. The Lancet [Internet]. 2017 Jul
1 [cited 2022 Jul 23];390(10089):2. Available from: https://www.thelancet.com/journals/lancet/article/PIIS01406736(17)31751-8/fulltext

4. Kasturiratne A, Wickremasinghe AR, Silva N de, Gunawardena NK, Pathmeswaran A, Premaratna R, et
al. The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of

Page **24** of **30**

423	Enveno	ming and Deaths. PLOS Med [Internet]. 2008 Nov 4 [cited 2023 Aug 18];5(11):e218. Available from:
424	https://j	ournals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0050218
425	5.	Slagboom J, Kool J, Harrison RA, Casewell NR. Haemotoxic snake venoms: their functional activity,
426	impact	on snakebite victims and pharmaceutical promise. Br J Haematol [Internet]. 2017 [cited 2023 Aug
427	18];177	(6):947–59. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.14591
428	6.	Schrire L, Muller GJ, Pantanowitz L. The diagnosis and treatment of envenomation in South Africa.
429	South A	African Institute for Medical Research; 1996.
430	7.	Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev.
431	2015;29	9(2):82–9.
432	8.	Kumar A, Gopalakrishnan M, Kuri HR, Bajpayee A, Kothari N, Garg MK. Case Report: Delayed Diffuse
433	Alveola	ar Hemorrhage in Echis sochureki Envenoming, Jodhpur, India. Am J Trop Med Hyg [Internet]. 2022 Jan
434	31 [cit	ed 2023 Aug 18]; Available from: https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-
435	ajtmh.2	1-1187/article-10.4269-ajtmh.21-1187.xml
436	9.	Krishnadas T, Sasidharan PK. SNAKE BITES IN NORTH KERALA, DEMOGRAPHIC PROFILE
437	AND N	MEAURSES FOR PREVENTION. J Evol Med Dent Sci [Internet]. 2014 Jan 27 [cited 2023 Aug
438	18];3(4):990–9. Available from:

https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=22784748&v=2.1&it=r&id=GALE%7CA646117896&sid=
googleScholar&linkaccess=abs

10. Zengin S, Yilmaz M, Al B, Yildirim C, Yarbil P, Kilic H, et al. Plasma exchange as a complementary
approach to snake bite treatment: an academic emergency department's experiences. Transfus Apher Sci Off J
World Apher Assoc Off J Eur Soc Haemapheresis. 2013 Dec;49(3):494–8.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Oct
20];372:n71. Available from: https://www.bmj.com/content/372/bmj.n71

447 12. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and
448 case reports. BMJ Evid-Based Med. 2018 Apr;23(2):60–3.

Page **25** of **30**

449	13. Yildirim C, Bayraktaroğlu Z, Gunay N, Bozkurt S, Köse A, Yilmaz M. The use of therapeuti
450	plasmapheresis in the treatment of poisoned and snake bite victims: an academic emergency department'
451	experiences. J Clin Apheresis. 2006 Dec;21(4):219–23.

- 452 14. Arora P, Belwal S, Uniyal B, Saxena S. Plasmapheresis in a case of acute kidney injury with severe
 453 hemolysis and thrombocytopenia due to hematotoxic (Russell's viper) snake bite. Saudi J Kidney Dis Transplant.
 454 2020;31(1):276–80.
- 455 15. Mohan G, Guduri PR, Shastry S. Role of therapeutic plasma exchange in snake bite associated
 456 thrombotic microangiopathy-A case report with review of literature. J Clin Apheresis. 2019 Aug;34(4):507–9.
- 457 16. Berber I, Korkmaz S, Sarici A, Erkurt MA, Kuku I, Kaya E, et al. Therapeutic plasma exchange for
 458 envenomation: Is it reasonable? Transfus Apher Sci. 2021;60(5):103241.
- **459** 17. Dineshkumar T, Dhanapriya J, Sakthirajan R, Thirumalvalavan K, Kurien AA, Balasubramaniyan T, et
- al. Thrombotic microangiopathy due to Viperidae bite: Two case reports. Indian J Nephrol. 2017;27(2):161.
- 461 18. Erkurt MA, Kuku I, Kaya E, Ozgen U, Berber I, Koroglu M, et al. Therapeutic plasma-exchange in
 462 hematologic disease: results from a single center in Eastern Anatolia. Transfus Apher Sci. 2013;48(3):335–9.
- Rathnayaka RN, Ranathunga PAN, Kularatne SAM, Sugathadasa K. Therapeutic plasma exchange for
 venom-induced thrombotic microangiopathy following hump-nosed pit viper (genus: Hypnale) bites: a
 prospective observational study. Wilderness Environ Med. 2022;33(4):386–98.
- 466 20. Isbister GK, Little M, Cull G, McCoubrie D, Lawton P, Szabo F, et al. Thrombotic microangiopathy
 467 from Australian brown snake (Pseudonaja) envenoming. Intern Med J. 2007 Aug;37(8):523–8.
- 468 21. Rahmani TRI, Nasasra T, Fuchs L, Almog Y, Lurie Y, Galante O. Acute thrombotic microangiopathic
 469 kidney injury due to Echis coloratus envenomation. Clin Toxicol Phila Pa. 2020 Apr;58(4):284–6.
- 470 22. Obeidat MB, Al-Swailmeen AM, Al-Sarayreh MM, Rahahleh KM. Thrombotic microangiopathy
 471 following Arabian saw-scaled viper (Echis coloratus) bite: Case report. Am J Case Rep. 2020;21:e922000-1.
- 472 23. Keyler DE. Envenomation by the lowland viper (Proatheris superciliaris): severe case profile
 473 documentation. Toxicon. 2008;52(8):836–41.
- 474 24. Kornalík F, Vorlová Z. Non-specific therapy of a hemorrhagic diathesis after a bite by a young Bothrops
 475 asper (barba amarilla): a case report. Toxicon Off J Int Soc Toxinology. 1990;28(12):1497–501.

Page **26** of **30**

476 25. Valenta J, Stach Z, Kolář M. Envenoming after a snakebite from the Northeast African saw-scaled viper
477 Echis pyramidum: prolonged therapy upon failed treatment by antivenom. Prague Med Rep. 2011;112(3):226–
478 35.

479 26. Sampley S, Sakhuja V, Bhasin D, Singh K, Singh H. Plasmapheresis for pulmonary hemorrhage
480 following viperine snakebite: a case report with review of literature. Indian J Crit Care Med Peer-Rev Off Publ
481 Indian Soc Crit Care Med. 2020;24(10):986.

482 27. Grace M, Jacob KJ, Jayakumar, P. A. Secondary capillary leak syndrome - Plasmapheresis: Is it the
483 answer? | International Archives of Integrated Medicine | EBSCOhost [Internet]. Vol. 2. 2015 [cited 2024 Jun 30].

484 p. 187. Available from:

485 https://openurl.ebsco.com/contentitem/gcd:102145212?sid=ebsco:plink:crawler&id=ebsco:gcd:102145212

486 28. Hameed S, Memon M, Khan S. Guillain-Barre Syndrome Following a Snakebite: A Case Report and
487 Review of Literature. Cureus [Internet]. [cited 2023 Oct 20];11(7):e5278. Available from:
488 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764639/

29. Cobcroft RG, Williams A, Cook D, Williams DJ, Masci P. Hemolytic uremic syndrome following taipan
envenomation with response to plasmapheresis. Pathology (Phila) [Internet]. 1997 [cited 2023 Oct 20];29(4):399–
402. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0031302516349893

492 30. Chuang TY, Lin SW, Chan RC. Guillain-Barré syndrome: an unusual complication after snake bite. Arch
493 Phys Med Rehabil. 1996 Jul;77(7):729–31.

Withana M, Rodrigo C, Gnanathasan A, Gooneratne L. Presumptive thrombotic thrombocytopenic
purpura following a hump-nosed viper (Hypnale hypnale) bite: a case report. J Venom Anim Toxins Trop Dis.
2014;20(1):1–6.

497 32. Mitrakrishnan JY, Bandula CW, Mitrakrishnan CS, Somaratna K, Jeyalakshmy S. Haemolytic uremic
498 syndrome a hitherto unreported complication of humpnosed viper envenomation. Indian J Hematol Blood
499 Transfus Off J Indian Soc Hematol Blood Transfus. 2013 Jun;29(2):116–8.

33. Rathnayaka RN, Ranathunga PAN, Kularatne SA. Thrombotic microangiopathy, hemolytic uremic
syndrome, and thrombotic thrombocytopenic purpura following hump-nosed pit viper (Genus: Hypnale)
envenoming in Sri Lanka. Wilderness Environ Med. 2019;30(1):66–78.

Page **27** of **30**

- 503 34. Srivastava A, Taly AB, Gupta A, Moin A, Murali T. Guillain-Barré syndrome following snake bite: An
- unusual complication. Ann Indian Acad Neurol [Internet]. 2010 [cited 2023 Oct 20];13(1):67–8. Available from:
- 505 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859593/
- 506 35. Reddy SP, Phadnis SA, Kumari P, Sharma N, Sethi J, Pannu AK, et al. Thrombotic microangiopathy in
- 507 Russel's viper envenomation. QJM Int J Med. 2022;115(7):486–7.
- 508 36. Cañas CA, Vecino MJ, Posso-Osorio I. Atypical Hemolytic Uremic Syndrome in a Patient With
- 509 Bothrops asper Envenomation. Wilderness Environ Med [Internet]. 2022 Mar 1 [cited 2023 Jul 28];33(1):109–
- 510 15. Available from: https://www.sciencedirect.com/science/article/pii/S108060322100168X
- 511 37. Namal Rathnayaka RMMK, Nishanthi Ranathunga PEA, Kularatne SAM. Thrombotic Microangiopathy
- Following Hypnale zara (Hump-Nosed Pit Viper) Envenoming: The First Known Case Report from Sri Lanka.
 Wilderness Environ Med [Internet]. 2020 Mar 1 [cited 2023 Jul 28];31(1):71–7. Available from: https://www.sciencedirect.com/science/article/pii/S1080603219301619
- 515 38. GodavarI KSV. Hemolytic Uremic Syndrome-An unusual complication of snake envenomation. Univ J
 516 Med Med Spec. 2016;2(2).
- Murthy PR, Ak AK, Karanth S, Kalashetty M. Thrombotic thrombocytopenic purpura in a patient with
 snake bite. Indian J Case Rep [Internet]. 2019 Jun 28 [cited 2024 Jun 30];5(3):277–9. Available from:
 https://mansapublishers.com/index.php/ijcr/article/view/1615
- 40. Wijewickrama ES, Gooneratne LV, Gnanathasan A, Gawarammana I, Gunatilake M, Isbister GK.
 Thrombotic microangiopathy and acute kidney injury following Sri Lankan Daboia russelii and Hypnale species
 envenoming. Clin Toxicol Phila Pa. 2020 Oct;58(10):997–1003.
- 41. Janarthanam MJ. Interesting case of AIDP following snake bite. Univ J Med Med Spec. 2016;2(5).
- 524 42. Senthilkumaran S, Miller SW, Williams HF, Thirumalaikolundusubramanian P, Vaiyapuri S, Patel K.
- 525 Hirata's disease (insulin autoimmune syndrome) following envenomation by a common krait. Toxicon Off J Int
 526 Soc Toxinology. 2022 Nov;219:106923.
- 43. Priyankara S, Rathnasiri V, Mihiran T, Premawansa G, Isbister GK, Silva A. Mild venom-induced
 consumption coagulopathy associated with thrombotic microangiopathy following a juvenile Russell's viper
 (Daboia russelii) envenoming: A case report. Toxicon Off J Int Soc Toxinology. 2022 Jun;212:8–10.

Page **28** of **30**

- 530 44. Laothong C, Sitprija V. Decreased parasympathetic activities in Malayan krait (Bungarus candidus)
 531 envenoming. Toxicon Off J Int Soc Toxinology. 2001 Sep;39(9):1353–7.
- 45. Herath N, Wazil A, Kularatne S, Ratnatunga N, Weerakoon K, Badurdeen S, et al. Thrombotic
 microangiopathy and acute kidney injury in hump-nosed viper (Hypnale species) envenoming: A descriptive study
 in Sri Lanka. Toxicon [Internet]. 2012 Jul 1 [cited 2023 Jul 28];60(1):61–5. Available from:
- 535 https://www.sciencedirect.com/science/article/pii/S0041010112000876
- 46. Bava D, Kumar PHA, Gupta A, Mandal S, Bajpayee A, Gopalakrishnan M, et al. Redefining the role of
- therapeutic plasma exchange in complications of Echis carinatus sochureki envenomation refractory to anti-snake
- venom: A case series. Asian J Transfus Sci. 2023;17(2):295–300.
- 539 47. Elmoqaddem A, Mrani Alaoui N, Cherrad. M. Hmidi T, Choumi F, Nadour K. Plasma Exchange in a
- Patient with a Severe Viper Bite. Saudi J Med Pharm Sci [Internet]. 2021 Jan 16 [cited 2024 Jun 30];7(1):50–1.
- 541 Available from: https://saudijournals.com/media/articles/SJMPS_71_50-51.pdf
- 542 48. Casamento AJ, Isbister GK. Thrombotic microangiopathy in two tiger snake envenomations. Anaesth
 543 Intensive Care. 2011;39(6):1124–7.
- 49. Chugh KS. Snake-bite-induced acute renal failure in India. Kidney Int. 1989 Mar;35(3):891–907.
- 545 50. Bull BS, Rubenberg ML, Dacie JV, Brain MC. Microangiopathic haemolytic anaemia: mechanisms of
 546 red-cell fragmentation: in vitro studies. Br J Haematol. 1968 Jun;14(6):643–52.
- 547 51. Malaque CMS, Duayer IF, Santoro ML. Acute kidney injury induced by thrombotic microangiopathy in
 548 two cases of Bothrops envenomation. Clin Toxicol. 2019;57(3):213–6.
- 549 52. Bucaretchi F, Pimenta MMB, Borrasca-Fernandes CF, Prado CC, Capitani EMD, Hyslop S. Thrombotic
 550 microangiopathy following Bothrops jararaca snakebite: case report. Clin Toxicol. 2019;57(4):294–9.
- 551 53. Okuda D, Nozaki C, Sekiya F, Morita T. Comparative Biochemistry of Disintegrins Isolated from Snake 552 Venom: Consideration of the Taxonomy and Geographical Distribution of Snakes in the Genus Echis1. J Biochem 553 (Tokyo) [Internet]. 2001 [cited 2023 Oct 20];129(4):615-20. Available from: Apr 1 554 https://doi.org/10.1093/oxfordjournals.jbchem.a002898

Page 29 of 30

555	54. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles
556	and capillaries: an undescribed disease. Arch Intern Med [Internet]. 1925 Jul 1 [cited 2023 Oct 20];36(1):89-93.
557	Available from: https://doi.org/10.1001/archinte.1925.00120130092009
558	55. Clark WF. Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange.
559	Semin Dial [Internet]. 2012 Mar [cited 2023 Oct 20];25(2):214–9. Available from:
560	https://onlinelibrary.wiley.com/doi/10.1111/j.1525-139X.2011.01035.x
561	56. Neil J, Choumet V, Le Coupanec A, d'Alayer J, Demeret S, Musset L. Guillain-Barre syndrome: first
562	description of a snake envenomation aetiology. J Neuroimmunol. 2012 Jan 18;242(1-2):72-7.
563	57. Aneja: Idiopathic systemic capillary leak syndrome - Google Scholar [Internet]. [cited 2024 Jun 30].
564	Available from:
565	$https://scholar.google.com/scholar_lookup?journal=UpToDate&title=Idiopathic+systemic+capillary+leak+syndic system is a straight of the system in the system is a straight of the system is a straigh$
566	rome&author=R+Aneja&author=S+Manaker&author=G+Finlay&
567	58. Udayabhaskaran V, Arun Thomas ET, Shaji B. Capillary Leak Syndrome Following Snakebite
568	Envenomation. Indian J Crit Care Med [Internet]. 2017 Oct;21(10):698-702. Available from: https://search-
569	ebscohost-
570	com.elibraryaiimsrishikesh.remotexs.in/login.aspx?direct=true&db=ccm&AN=125851540&site=ehost-live
571	59. Adamski J. Thrombotic microangiopathy and indications for therapeutic plasma exchange. Hematology
572	[Internet]. 2014 Dec 5 [cited 2023 Oct 20];2014(1):444–9. Available from:
573	https://ashpublications.org/hematology/article/2014/1/444/20443/Thrombotic-microangiopathy-and-indications-
574	for
575	60. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on
576	the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of
577	the American Society for Apheresis: The Seventh Special Issue. J Clin Apheresis. 2016 Jun;31(3):149-62.
578	61. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis Off J Natl Kidney
579	Found. 2008 Dec;52(6):1180–96.
580	62. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J
581	Kidney Dis Off J Natl Kidney Found. 1994 Jun;23(6):817–27.

Page **30** of **30**

582	63. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al.
583	Guidelines on the use of therapeutic apheresis in clinical practiceevidence-based approach from the Apheresis
584	Applications Committee of the American Society for Apheresis. J Clin Apheresis. 2010;25(3):83–177.
585	
586	
587	
588	
589	